Sabby Management’s Purple Biotech PPBT Stock Holding History

Sabby Management’s Portfolio PPBT Stock Details PPBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	-$138K	–	144
2022 Q1	$138K	Sell	2 -3	-60%	-$1.94K	0.02%	108
2021 Q4	$366K	Buy	5 +4	+400%	+$3.41K	0.05%	117
2021 Q3	$57K	Sell	1 -9	-90%	-$8.72K	0.01%	168
2021 Q2	$1.01M	Hold	10	–	–	0.14%	81
2021 Q1	$805K	Buy	+10	New	+$9.34K	0.16%	88

Other funds holding PPBT

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WTB

Washington Trust Bank Spokane, Washington $1.36B AUM 21.14% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VVP

Venture Visionary Partners Sylvania, Ohio $3.6B AUM 30.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Sabby Management's PPBT Position: Q2 2022 in Review

Sabby Management sold out of Purple Biotech (PPBT) in Q2 2022, closing a stake of 133 shares — an estimated $105K sold.

Sabby Management first reported a position in PPBT in Q2 2016 and held it in 7 quarters. The position peaked at $725K in Q2 2016. 12 funds tracked by Wall St. Rank hold PPBT as of Q2 2022.

Sabby Management reported no remaining Purple Biotech position as of Q2 2022 after selling out during the quarter.
Sabby Management sold 133 Purple Biotech shares in Q2 2022, an estimated $105K.
Sabby Management first reported a position in Purple Biotech in Q2 2016 and held it in 7 quarters.
Sabby Management's Purple Biotech position peaked at $725K in Q2 2016.
12 funds tracked by Wall St. Rank held Purple Biotech as of Q2 2022.

Based on Sabby Management's 13F filing for Q2 2022, filed 15 Aug 2022.